Soluble forms of RAGE: An index of vascular stress?. A commentary on "Soluble RAGE in type 2 diabetes: Association with oxidative stress"

Free Radical Biology and Medicine

Volumn 43, Issue 4, 2007, Pages 506-510

  Nawroth, Peter P ^a   Stern, David M ^b  

^a Department of Medicine I and Clinical Chemistry ^*  (Germany)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Free radicals

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

EID: 34447297291     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.04.014     Document Type: Note

References (26)

1. Koch A., Halloran M., Haskell C., Shah M., and Polverini P. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376 (1995) 517-519
2. Olson J., Whitelaw C., McHardy K., Pearson D., and Forrester J. Soluble leucocyte adhesion molecules in diabetic retinopathy stimulate retinal capillary endothelial cell migration. Diabetologia 40 (1997) 1166-1171
3. Byrne G., Ghellal A., Iddon J., Blann A., Venizelos V., Kumar S., Howell A., and Bundred N. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J. Natl. Cancer Inst. 92 (2000) 1329-1336
4. Blum A., Khazim K., Merei M., Peleg A., Blum N., and Vaispapir V. The Stroke Trial-can we predict clinical outcome of patients with ischemic stroke by measuring soluble cell adhesion molecules?. Eur. Cytokine Netw. 17 (2006) 295-298
5. Wang J., Zhou D., Li J., Zhang M., Deng J., Gao C., Li J., Lian Y., and Chen M. Association of soluble ICAM-1 with neurological deterioration of ischemic stroke: the Chongqing Stroke Study. Cerebrovasc. Dis. 21 (2006) 67-73
6. Schmidt A.-M., Yan S.-D., Yan S.-F., and Stern D.M. RAGE: a multiligand receptor serving as a progression factor amplifying the immune/inflammatory response. J. Clin. Invest. 108 (2001) 949-955
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
8. Chavakis T., Bierhaus A., Al-Fakhri N., Schneider D., Witte S., Linn T., Nagashima M., Morser J., Arnold B., Preissner K., and Nawroth P. The pattern recognition receptor RAGE is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 198 (2003) 1507-1515
9. Zhou Z., Immel D., Xi C.-X., Bierhaus A., Feng X., Mei L., Nawroth P., Stern D., and Xiong W.-C. Regulation of osteoclast function and bone mass by RAGE. J. Exp. Med. 203 (2006) 1067-1080
10. Wautier J.-L., Zoukourian C., Chappey O., Wautier M.-P., Guillausseau P.-J., Cao R., Hori O., Stern D., and Schmidt A.-M. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: sRAGE blocks hyperpermeability. J. Clin. Invest. 97 (1996) 238-243
11. Park L., Raman K., Lee K., Lu Y., Ferran L., Chow W., Stern D., and Schmidt A.-M. Suppression of accelerated diabetic atherosclerosis by soluble RAGE. Nat. Med. 4 (1998) 1025-1031
12. Liliensiek B., Weigand M., Bierhaus A., Nicklas W., Kasper M., Hofer S., Plachky J., Gröne H.-J., Schmidt A., Yan S.D., Martin E., Schleicher E., Stern D.M., Hämmerling G., Nawroth P.P., and Arnold B. RAGE regulating sepsis but not the adaptive immune response. J. Clin. Invest. 113 (2004) 1641-1650
13. Malherbe P., Richards J., Gaillard H., Thompson A., Diener C., Schuler A., and Huber G. cDNA cloning of a novel secreted isoform of human RAGE and characterization of cells co-expressing cell surface scavenger receptors and Swedish mutant APP. Brain Res. Mol. Brain Res. 71 (1999) 159-170
14. Yonekura H., Yamamoto Y., Sakurai S., Petrova R., Abedin M., Li H., Yasui K., Takeuchi M., Makita Z., Takasawa S., Okamoto H., Watanabe T., and Yamamoto H. Novel splice variants of RAGE expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370 (2003) 1097-1109
15. Park I., Yeon S., Youn J., Choi J., Sasaki N., Choi I., and Shin J.-S. Expression of a novel secreted splice variant of RAGE in human brain astrocytes and peripheral blood mononuclear cells. Mol. Immunol. 40 (2004) 1203-1211
16. Koyama H., Shoji T., Yokoyama H., Kotoyama K., Mori K., Fukumoto S., Emoto M., Shoji T., Tameik H., Matsuki H., Sakurai S., Yamamoto Y., Yonekura H., Watanabe T., Yamamoto H., and Nishizawa Y. Plasma level of esRAGE is associated with components of the metabolic syndrome and atherosclerosis. Atheroscler. Thromb. Vasc. Biol. 25 (2005) 2587-2593
17. Cheng C., Tsuneyama K., Kominami R., Shinohara H., Sakurai S., Yonekura H., Watanabe T., Takano Y., Yamamoto H., and Yamamoto Y. Expression profiling of esRAGE in human organs. Mod. Pathol. 18 (2005) 1385-1396
18. Humpert P., Djuric Z., Kopf S., Rudofsky G., Morcos M., Nawroth P., and Bierhaus A. sRAGE but not esRAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc. Diabetol. 6 (2007) 9-13
19. Falcone C., Emanuele E., D'Angelo A., Buzzi M., Belvito C., Cuccia M., and Geroldi D. Plasma levels of sRAGE and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1032-1037
20. Katakami N., Matsuhisa M., Kaneto H., Matsuoka T., Sakamoto K., Nakatani Y., Ohtoshi K., Hayaishi-Okano R., Kosugi K., Hori M., and Yamasaki Y. Decreased esRAGE in type 1 diabetic patients. Diabetes Care 28 (2005) 2716-2721
21. Basta G., Sironi A., Lazzerini G., DelTurco S., Buzzigoli E., Casolaro A., Natali A., Ferrannini E., and Gastaldelli A. Circulating sRAGE is inversely associated with glycemic control and S100A12 protein. J. Clin. Endocrinol. Metab. 91 (2006) 4628-4634
22. Emanuele E., D'Angelo A., Tomaino C., Binetti G., Ghidoni R., Politi P., Bernardi L., Maletta R., Bruni A., and Geroldi D. Circulating levels of sRAGE in Alzheimer disease and vascular dementia. Arch. Neurol. 62 (2005) 1734-1736
23. Kalousova M., Jachmyova M., Mestak O., Hodkova M., Kazderova M., Tesai V., and Zima T. RAGE-soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol. Dial. Transplant (2007) Epub ahead of print
24. Devangelio E., Santilli F., Formoso G., Ferroni P., Bucciarelli L., Michetti N., Clissa C., Ciabattoni G., Consoli A., and Davi G. sRAGE in type 2 diabetes: association with oxidative stress. Free Radic. Biol. Med. 43 (2007) 511-518
25. Forbes J., Thorpe S., Thallas-Bonke V., Pete J., Thomas M., Deemer E., Bassal S., El-Osta A., Long D., Panagiotopoulos S., Jerums G., Osicka T., and Cooper M. Modulation of sRAGE by ACE-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 16 (2005) 2363-2372
26. Pullerits R., Brisslert M., Jonsson I., and Tarkowski A. sRAGE triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum. 54 (2006) 3898-3907